Article
Inhibition of glycosphingolipid synthesis induces a profound reduction of plasma cholesterol and inhibits atherosclerosis development in APOE*3 Leiden and low-density lipoprotein receptor-/- mice.
Arteriosclerosis, thrombosis, and vascular biology - 1 May 2010
Bietrix Florence, Lombardo Elisa, van Roomen Cindy P A A, Ottenhoff Roelof, Vos Mariska, Rensen Patrick C N, Verhoeven Arthur J, Aerts Johannes M, Groen Albert K
Abstract excerpt
OBJECTIVE: The iminosugar N-(5'-adamantane-1'-yl-methoxy)-pentyl-1-deoxynoijirimycin (AMP-DNM), an inhibitor of the enzyme glucosylceramide synthase catalyzing glycosphingolipid (GSL) biosynthesis, ameliorates diabetes and reduces liver steatosis in ob/ob mice. Because an accumulation of sphingolipids, including sphingomyelin and GSLs, has been reported in atherosclerotic lesions in animal models and in humans,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.